{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:42:08Z","timestamp":1790786528390,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T00:00:00Z","timestamp":1572220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.omtm.2019.10.011","type":"journal-article","created":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T10:08:37Z","timestamp":1572775717000},"page":"359-370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["mRNA as a Novel Treatment Strategy for Hereditary Spastic Paraplegia Type 5"],"prefix":"10.1016","volume":"15","author":[{"given":"Stefan","family":"Hauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Poenisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Schelling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"H\u00f6flinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Teegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabea","family":"Betten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-\u00c5ke","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"H\u00fcbener-Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schlake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Chevessier-T\u00fcnnesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Horscroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingemar","family":"Bj\u00f6rkhem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Sch\u00f6ls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2019.10.011_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ana.24611","article-title":"Hereditary spastic paraplegia: Clinicogenetic lessons from 608 patients","volume":"79","author":"Sch\u00fcle","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2019.10.011_bib2","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ajhg.2007.10.001","article-title":"Sequence alterations within CYP7B1 implicate defective cholesterol homeostasis in motor-neuron degeneration","volume":"82","author":"Tsaousidou","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2019.10.011_bib3","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/brain\/awp073","article-title":"CYP7B1 mutations in pure and complex forms of hereditary spastic paraplegia type 5","volume":"132","author":"Goizet","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.omtm.2019.10.011_bib4","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1194\/jlr.M002543","article-title":"Marked accumulation of 27-hydroxycholesterol in SPG5 patients with hereditary spastic paresis","volume":"51","author":"Sch\u00fcle","year":"2010","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.omtm.2019.10.011_bib5","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1194\/jlr.R006338","article-title":"Genetic connections between neurological disorders and cholesterol metabolism","volume":"51","author":"Bj\u00f6rkhem","year":"2010","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.omtm.2019.10.011_bib6","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1093\/brain\/awx273","article-title":"Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trial","volume":"140","author":"Sch\u00f6ls","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.omtm.2019.10.011_bib7","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1172\/JCI68506","article-title":"Cholestenoic acids regulate motor neuron survival via liver X receptors","volume":"124","author":"Theofilopoulos","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2019.10.011_bib8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/brain\/awx297","article-title":"Plasma oxysterols: biomarkers for diagnosis and treatment in spastic paraplegia type 5","volume":"141","author":"Marelli","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.omtm.2019.10.011_bib9","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1194\/jlr.M200434-JLR200","article-title":"Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers","volume":"44","author":"Leoni","year":"2003","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.omtm.2019.10.011_bib10","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1126\/science.1546298","article-title":"Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA","volume":"255","author":"Jirikowski","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.omtm.2019.10.011_bib11","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in\u00a0vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.omtm.2019.10.011_bib12","first-page":"23","article-title":"Vaccination with messenger RNA","volume":"127","author":"Pascolo","year":"2006","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.omtm.2019.10.011_bib13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.4161\/rna.22269","article-title":"Developing mRNA-vaccine technologies","volume":"9","author":"Schlake","year":"2012","journal-title":"RNA Biol."},{"key":"10.1016\/j.omtm.2019.10.011_bib14","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics--developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtm.2019.10.011_bib15","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/mt.2015.103","article-title":"Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals","volume":"23","author":"Thess","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.10.011_bib16","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ymthe.2019.03.001","article-title":"Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy","volume":"27","author":"DeRosa","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.10.011_bib17","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ymthe.2019.03.002","article-title":"mRNA: A novel avenue to antibody therapy?","volume":"27","author":"Schlake","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.10.011_bib18","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.15252\/emmm.201707678","article-title":"mRNA mediates passive vaccination against infectious agents, toxins, and tumors","volume":"9","author":"Thran","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2019.10.011_bib19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.omtm.2019.10.011_bib20","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","article-title":"Systemic messenger RNA therapy as a treatment for methylmalonic acidemia","volume":"21","author":"An","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtm.2019.10.011_bib21","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/gt.2016.46","article-title":"Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system","volume":"23","author":"DeRosa","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2019.10.011_bib22","doi-asserted-by":"crossref","first-page":"E1941","DOI":"10.1073\/pnas.1619653114","article-title":"Systemic delivery of factor IX messenger RNA for protein replacement therapy","volume":"114","author":"Ramaswamy","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2019.10.011_bib23","first-page":"8247935","article-title":"SERPINA1 mRNA as a Treatment for Alpha-1 Antitrypsin Deficiency","volume":"2018","author":"Connolly","year":"2018","journal-title":"J.\u00a0Nucleic Acids"},{"key":"10.1016\/j.omtm.2019.10.011_bib24","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ymthe.2018.01.006","article-title":"G6PC mRNA therapy positively regulates fasting blood glucose and decreases liver abnormalities in a mouse model of glycogen storage disease 1a","volume":"26","author":"Roseman","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.10.011_bib25","doi-asserted-by":"crossref","first-page":"23937","DOI":"10.1074\/jbc.M011564200","article-title":"Neurosteroid hydroxylase CYP7B: vivid reporter activity in dentate gyrus of gene-targeted mice and abolition of a widespread pathway of steroid and oxysterol hydroxylation","volume":"276","author":"Rose","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2019.10.011_bib26","doi-asserted-by":"crossref","first-page":"16536","DOI":"10.1074\/jbc.M001811200","article-title":"Disruption of the oxysterol 7alpha-hydroxylase gene in mice","volume":"275","author":"Li-Hawkins","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2019.10.011_bib27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/cercor\/bhy274","article-title":"27-Hydroxycholesterol Induces Aberrant Morphology and Synaptic Dysfunction in Hippocampal Neurons","volume":"29","author":"Merino-Serrais","year":"2019","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.omtm.2019.10.011_bib28","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.bbr.2014.10.018","article-title":"27-hydroxycholesterol mediates negative effects of dietary cholesterol on cognition in mice","volume":"278","author":"Heverin","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.omtm.2019.10.011_bib29","doi-asserted-by":"crossref","first-page":"20019","DOI":"10.1038\/srep20019","article-title":"Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich\u2019s ataxia","volume":"6","author":"Nabhan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2019.10.011_bib30","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1529\/biophysj.106.083766","article-title":"Cubic phases in phosphatidylcholine-cholesterol mixtures: cholesterol as membrane \u201cfusogen\u201d","volume":"91","author":"Tenchov","year":"2006","journal-title":"Biophys. J."},{"key":"10.1016\/j.omtm.2019.10.011_bib31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1098\/rsif.2011.0356","article-title":"The effect of neutral helper lipids on the structure of cationic lipid monolayers","volume":"9","author":"Dabkowska","year":"2012","journal-title":"J.\u00a0R. Soc. Interface"},{"key":"10.1016\/j.omtm.2019.10.011_bib32","doi-asserted-by":"crossref","first-page":"18153","DOI":"10.1074\/jbc.273.29.18153","article-title":"Activities of recombinant human cytochrome P450c27 (CYP27) which produce intermediates of alternative bile acid biosynthetic pathways","volume":"273","author":"Pikuleva","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2019.10.011_bib33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/abio.1995.1110","article-title":"Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry","volume":"225","author":"Dzeletovic","year":"1995","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.omtm.2019.10.011_bib34","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/ng1105-1155","article-title":"EMPReSS: standardized phenotype screens for functional annotation of the mouse genome","volume":"37","author":"Brown","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtm.2019.10.011_bib35","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/bioinformatics\/bti441","article-title":"EMPReSS: European mouse phenotyping resource for standardized screens","volume":"21","author":"Green","year":"2005","journal-title":"Bioinformatics"}],"container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050119301196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050119301196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:23:59Z","timestamp":1762421039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050119301196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":35,"alternative-id":["S2329050119301196"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2019.10.011","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737035914.793582726","asserted-by":"object"}]},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA as a Novel Treatment Strategy for Hereditary Spastic Paraplegia Type 5","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2019.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s).","name":"copyright","label":"Copyright"}]}}